Sydney Vital is pleased to be hosting the 2020 Neuroendocrine Tumour Q&A Session.

The event will take place on Thursday 7th May, 2020 from 6pm – 8:30pm

The session provides the opportunity to hear about what’s new in Neuroendocrine cancers and why research plays a vital role in patient outcomes. There will be an opportunity to discuss with the Neuroendocrine Tumours Q&A panel of medical specialists, patient advocates and patients about people in our community who live with Neuroendocrine Tumours.

This is a FREE event and refreshments will be provided. If you cannot be there in person then a live-streaming Webcast will also be available via (Meeting ID: 998-007-477)

Reception 6:00 – 6:30 pm
Q&A Forum – 6:30 – 8:30 pm

Meter parking is available on Westbourne St.

Our panel of speakers will include:

A/Prof Nick Pavlakis, Medical Oncologist

A/Prof Nick Pavlakis underwent medical training at the University of NSW and graduated in 1991. He underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997. He then spent 3 years completing a PhD in new cancer drug development and a Masters of Clinical Epidemiology through the University of Sydney. He has been on staff in the Department of Medical Oncology at Royal North Shore Hospital since 2001 and has been Head of Department and Head of the Clinical Trials Unit since 2008. He has worked in private oncology practice since 1998 and a practice member of the Northern Cancer Institute since 2001. He has previously served on the Executive of the Medical Oncology Group of Australia (MOGA), the Private Cancer Physicians Group of Australia (PCPA), the Australian Lung Cancer Trials Group and on Advisory boards for colorectal and lung cancers and new cancer drugs.

Prof Dale Bailey, Principal Physicist

Professor Dale Bailey is a principal physicist in the Department of Nuclear Medicine at Royal North Shore Hospital and Professor in Medical Radiation Science at the University of Sydney.

He earned undergraduate and master’s degree in physics from the University of Technology (UTS), Sydney and his doctorate from the University of Surrey (UK). Prior to his current position, Professor Bailey has also held research appointments at Harvard Medical School, with the Medical Research Council (UK) at Hammersmith Hospital, London and Guy’s & St Thomas’ Hospital.

Dr David Chan, Medical Oncologist

Dr David Chan is a medical oncologist and researcher with clinical and research interests in gastrointestinal cancers and neuroendocrine tumours. He is a medical oncologist at GenesisCare St Leonards, Royal North Shore Hospital and North Shore Private Hospital.

David completed his medical degree at the University of New South Wales and completed his FRACP in Medical Oncology at Royal North Shore Hospital. He then completed a neuroendocrine tumour fellowship in Sunnybrook Health Sciences Centre, Toronto, and subsequently submitted a PhD in NETs back in Sydney. He is the current chair of the NET group at the Clinical Oncology Society of Australia, and holds an NHMRC grant to improve the use of PET imaging in NETs.

A/Prof Paul Roach, Nuclear Medicine Physician

A/Prof Paul Roach obtained his medical qualifications with honours from the University of Sydney and completed his residency training at Royal North Shore Hospital. He then undertook specialty training in Nuclear Medicine at Royal North Shore Hospital, Royal Prince Alfred Hospital and Harvard Medical School in Boston, U.S.A. (working at such prestigious institutions as the Brigham & Women’s Hospital, the Dana Farber Cancer Institute, Beth Israel Hospital and the Childrens’ Hospital, Boston). Subsequently, he has undergone training in PET imaging at St Thomas’ Hospital, London.

Meredith Cummins, Representative, NeuroEndocrine Cancer Australia

Meredith is a highly driven and dedicated health professional who thrives on delivering world class care to cancer patients and enhancing the skills of other health professionals to deliver this care. She has been involved in Oncology for the past 30 years in metropolitan, rural, international, public and private settings. In the past 15 years she has been a key player instrumental in the commissioning and establishment of four private cancer care facilities in New South Wales.